Please use this identifier to cite or link to this item:
Title: Pharmacogenomic effects of β-blocker use on femoral neck bone mineral density
Authors: Nevola, Kathleen T.
Nagarajan, Archana
Hinton, Alexandra C.
Trajanoska, Katerina
Formosa, Melissa Marie
Xuereb-Anastasi, Angela
Velde, Nathalie van der
Stricker, Bruno H.
Rivadeneira, Fernando
Fuggle, Nicholas R.
Westbury, Leo D.
Dennison, Elaine M.
Cooper, Cyrus
Kiel, Douglas P.
Motyl, Katherine J.
Lary, Christine W.
Keywords: Adrenergic beta blockers
Bone density
Issue Date: 2021
Publisher: Oxford University Press
Citation: Nevola, K., Nagarajan, A., Hinton, A., Trajanoska, K., Formosa, M., Xuereb-Anastasi, A., ... Lary, C. (2021). Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density. Journal of the Endocrine Society, 5(8), Bvab092.
Abstract: CONTEXT: Recent studies have shown that β-blocker (BB) users have a decreased risk of fracture and higher bone mineral density (BMD) compared to nonusers, likely due to the suppression of adrenergic signaling in osteoblasts, leading to increased BMD. There is also variability in the effect size of BB use on BMD in humans, which may be due to pharmacogenomic effects.
OBJECTIVE: To investigate potential single-nucleotide variations (SNVs) associated with the effect of BB use on femoral neck BMD, we performed a cross-sectional analysis using clinical data, dual-energy x-ray absorptiometry, and genetic data from the Framingham Heart Study’s (FHS) Offspring Cohort. We then sought to validate our top 4 genetic findings using data from the Rotterdam Study, the BPROOF Study, the Malta Osteoporosis Fracture Study (MOFS), and the Hertfordshire Cohort Study.
METHODS: We used sex-stratified linear mixed models to determine SNVs that had a significant interaction effect with BB use on femoral neck (FN) BMD across 11 gene regions. We also evaluated the association of our top SNVs from the FHS with microRNA (miRNA) expression in blood and identified potential miRNA-mediated mechanisms by which these SNVs may affect FN BMD.
RESULTS: One variation (rs11124190 in HDAC4) was validated in females using data from the Rotterdam Study, while another (rs12414657 in ADRB1) was validated in females using data from the MOFS. We performed an exploratory meta-analysis of all 5 studies for these variations, which further validated our findings.
CONCLUSION: This analysis provides a starting point for investigating the pharmacogenomic effects of BB use on BMD measures.
Appears in Collections:Scholarly Works - FacHScABS

Files in This Item:
File Description SizeFormat 
Pharmacogenomic effects of β-blocker use on femoral neck bone mineral density.pdf482.13 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.